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The cardiovascular system encompasses the extensive network 
that supplies the body with the nutrients and oxygen it needs to 
function. At the center of this complex system, the heart serves 
as an anatomical pump to push the blood out of its chambers and 
throughout the body. The sinoatrial node stimulates the cardiac 
muscle to contract periodically, and its normal rhythm can be 
measured on an electrocardiogram (ECG). In the presence of 
cardiac dysfunction, this test can indicate specific abnormalities 
in the sinus rhythm. The left ventricle is the heart’s main pump-
ing chamber, and a weakening or abnormality in its function can 
produce severe repercussions. There are multiple causes of left 
ventricular dysfunction. In the case of Takotsubo cardiomyopathy 
(TTC), sources like coronary artery spasm, microvascular dys-
function, and catecholamine excess are suspected to contribute 
to its pathogenesis (Komamura, et al. 2014). These theories are 
evaluated and debated in many recent studies that seek to discov-
er the likely origin and development of TTC.
The syndrome was first described in 1990 by a Japanese car-
diologist which prompted its name, Takotsubo cardiomyopathy 
(Sato, et al. 1990). Translated from Japanese to “octopus trap”, 
takotsubo describes the shape of the left ventricle during sys-
tole in many patients suffering from TTC. Resembling its name-
sake’s rounded bottom and narrow neck, TTC most commonly 
appears with apical ballooning and mid-ventricle hypokinesis. 
TTC is also known as stress-induced cardiomyopathy, ampul-
la cardiomyopathy, transient left ventricular apical ballooning, 
and broken heart syndrome. The latter title indicates the likely 
presence of an emotional or physical trigger that precipitates 
the condition. Researchers found stressors such as the sudden 
death of a loved one, anxiety over a family member’s congeni-
tal disorders, and vigorous excitation to be responsible for the 
onset of TTC in some of their subjects (Tsuchihashi, et al. 2001). 
There are instances where no physical or emotional stressor is 
indicated and the trigger is unknown (Gianni, et al. 2006).
Epidemiology
This specific cardiomyopathy is a relatively new diagnosis with 
the number of published cases growing in the past 20 years. The 
condition occurs predominantly in postmenopausal women 
which lends to one of the pathogenic theories of TTC regarding 
lack of estrogen and its effects on catecholamine levels in the 
body (Komamura, et al. 2014). A study found a 6.3-fold high-
er incidence of the condition in women than in men, differing 
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Figure 1  Left ventriculogram exhibiting Takotsubo  A: end-diastolic 
phase; B: end-systolic phase  Here, the apex shows akinesis with 
visible hypercontraction of the basal portion  C: Takotsubo, an 
octopus trap  (Akashi, et al  2008)
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from the usual male dominance in coronary artery diseases 
(Tsuchihashi, et al. 2001). A systematic review of 14 studies 
found that 88.8% of TTC patients were women, leaving signif-
icant room for a pathogenic mechanism that can explain the 
specific epidemiology of TTC.
Clinical Manifestations
Takotsubo cardiomyopathy’s most common symptomatic pre-
sentation includes severe chest pain and dyspnea, resembling the 
symptoms of an acute myocardial infarction (Komamura, et al. 
2014). Where myocardial infarctions are generally preceded by 
atherosclerosis, plaque buildup in arteries, TTC is excluded as a 
diagnosis in patients that present with artery blockage or a histo-
ry of obstructive coronary artery disease. A study found 90% of 
its subjects without preceding conditions admitted to chest pain 
or discomfort with the onset of TTC (Tsuchihashi, et al. 2001). 
Serum level indication using cardiac biomarkers found creatine 
kinase and troponin T to be elevated in many cases, indicating a 
heart muscle abnormality. Creatine kinase expressed in cardiac 
muscle is used to assay damage to the heart in various cardiac 
conditions. In TTC, there is a slight elevation from the normal 
22-198 IU/l (Tsuchihashi, et al. 2001). Troponin T, a cardiac protein 
released when the heart muscle is damaged, is found to be simi-
larly elevated (Gianni, et al. 2006). In 86.5% of patients with TTC, 
left ventricular ejection fraction was reduced to 40.7±11.2% from 
its normal 55% or higher. Studies also note increased left ventric-
ular end-diastolic pressure in 93% of patients with this condition 
(Templin, et al. 2015) (Tsuchihashi, et al. 2001).
Diagnosis
According to Heart Failure Association’s diagnostic criteria, pa-
tients need to fulfill the following specifications for their condi-
tion to be classified as TTC. The first is the presence of a wall mo-
tion abnormality involving the dyskinesis, hypokinesis or akenesis 
of the left ventricle mid segments. This includes the ballooning of 
the apex as it fails to contract. Echocardiograms or cardiac ven-
triculography can be used to identify this cardiomyopathy (Abe, et 
al. 2003). In addition, TTC is indicated only in the absence of ob-
structive coronary disease and acute plaque rupture and can be 
determined using angiographic images of the coronary arteries. 
This exclusion differentiates TTC from a myocardial infarction, a 
heart attack, which is caused by acute plaque ruptures and pres-
ents with similar symptoms. The third criteria for the diagnosis 
includes the appearance of new, reversible sinus rhythm changes 
on the patient’s ECG. Most commonly, the condition appears with 
ST-segment elevation and T wave inversion (Gianni, et al. 2006). 
Another criterion is the significant elevation of serum natriuretic 
peptide (BNP or NT-proBNP), a blood indicator of heart failure. 
Bloodwork to assess cardiac enzyme levels like Troponin T is also 
used in the diagnosis of TTC. Perhaps the most important as-
pect of diagnosing a patient with TTC is the transient nature of 
the condition. Essentially, the patient should recover full cardiac 
function within a week of the acute episode. If a patient does not 
recover full systolic function within 12 weeks, a different diagnosis 
should be considered (Komamura, et al. 2014).
The Mayo Clinic’s diagnostic criteria includes the absence of 
pheochromocytoma, a hormone releasing tumor of the adrenal 
glands. If a patient presented with additional symptoms such as 
sweating, tachycardia, and headaches, pheochromocytoma was 
suspected (Reeder, Prasad, 2017). However, the updated conclu-
sive criteria released by the Heart Failure Association, allows for 
pheochromocytoma as a trigger for TTC in the event that it pre-
cipitates a catecholamine storm (Ansari, El-Battrawy, 2017). Mayo 
Clinic also addresses the exclusion of myocarditis, inflammation 
of the myocardium, as part of its diagnostic criteria. Myocarditis 
involves slower recovery than TTC and can be excluded with the 
absence of scarring and myocardial inflammation on cardiovas-
cular magnetic resonance imaging (MRI). MRI also confirms the 
reversible wall motion abnormalities and the quantification of the 
ventricular function in a patient with suspected TTC.
Management
Due to its transient nature, TTC can often be managed by 
addressing and alleviating the physical or emotional stressors 
that triggered the onset of the cardiomyopathy. Although there 
are not any conclusive treatments, treatments generally admin-
istered for heart failure such as beta blockers, ACE inhibitors, 
and diuretics, are often administered as supportive care for 
TTC patients. A possible treatment specified for older women 
is estrogen administration. This was found to be beneficial in an 
animal model of TTC, though clinical trials have not yet been 
performed. The general prognosis of TTC is positive, but com-
plications have occurred in many patients ranging from cardio-
genic shock and left ventricular outflow tract obstruction, to 
severe systolic dysfunction. Diagnosis and management of these 
conditions is imperative to reduce the fatalities attributed to 
TTC (De Backer, et al. 2014).
Methods
The research in this paper was compiled using the online data-
bases, Pubmed and UpToDate, and through Touro’s online library 
system for access to databases Proquest and Ebsco. Keywords 
Takotsubo cardiomyopathy and Broken heart syndrome were 
used in the initial research of this paper. Careful analysis of 
the gathered material prompted further research using sourc-
es cited in articles on this topic. Both peer reviewed articles 
and clinical studies were analyzed to evaluate the hypothesized 
pathogenic mechanisms of Takotsubo cardiomyopathy.
Discussion
When evaluating the pathogenesis of TTC, researchers are 
faced with various differentiating origins and pathways that TTC 
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can develop from. A worldwide investigation of patients with 
TTC has led to several possible theories of the cardiomyopathy 
including a coronary artery spasm, catecholamine excess, and 
microvascular dysfunction. While studies have produced results 
that support all three theories, there is still a significant amount 
of research required to determine the definitive pathogenic 
mechanism of TTC.
Coronary Artery Spasm
The heart is a recipient of its own labor in its utilization of 
its blood supply from the coronary arteries. In order for the 
heart muscle to function, the correct amount of blood supply 
in regular increments must be delivered through these arteries. 
Many have hypothesized that an abnormality in this cycle is the 
source of TTC in the form of a coronary artery spasm. A coro-
nary artery spasm is a temporary contracting of the wall of the 
artery that constricts blood flow and leads to decreased blood 
supply to the heart muscle. The occlusion or near occlusion of 
the vessel can cause decreased muscle movement in the heart 
chambers that depend on the regular blood supply from the 
coronary arteries.
Studies performed on patients with TTC support this the-
ory. In one case study, a 79-year-old man was admitted to a 
hospital presenting with three consecutive days of chest pain. 
Echocardiography showed hyperkineses in the basal wall and 
akenesis in the apex of the left ventricle. In order to locate the 
source of the cardiomyopathy, doctors performed provocative 
testing using ergonovine, a muscle contractant. The diagnostic 
screening test induced a right coronary artery spasm and re-
sulted in ECG changes with increased ST segment elevation 
in leads II, III, and aVF. The patient’s normal left ventricle wall 
motion was restored one week later, and he was subsequently 
diagnosed with TTC with a pathogenesis attributed to a coro-
nary artery spasm (Misumi, et al. 2010). 
Although there are many cases of patients with TTC experi-
encing induced coronary artery spasm from provocative testing 
using either ergonovine or acetylcholine, there are more that 
have not. Many patients with TTC did not present with increased 
susceptibility to ergonovine or acetylcholine in provocative 
testing, and according to reports, only 30% of patients present-
ed characteristics of a vasospasm with testing (Komamura, et 
al. 2014). This research leaves a substantial gap in the coronary 
artery spasm theory (Madias, 2014). Nonetheless, the presence 
of coronary vasospasm in some TTC patients cannot be ignored 
and this theory has therefore not been completely dismissed. 
Microvascular Dysfunction
Another theory explored as a pathogenic mechanism of TTC 
is microvascular dysfunction. The primary obstacle in explor-
ing this mechanism is the limited technology available to eval-
uate microvascular function. One study was performed using 
the Thrombolysis In Myocardial Infarction (TIMI) frame count 
technique, a quantitative, continuous variable that assesses flow 
changes by counting the cineframes it takes for contrast to 
reach coronary landmarks. Researchers evaluated the flow of 
the left anterior descending artery, left circumflex artery, and 
the right coronary artery in order to suggest diffuse impaired 
coronary microcirculation in the myocardium. In 23 of the 24 
patients studied, there was a slowdown in coronary microcir-
culation noted (Fazio, et al. 2010). A more recent assessment 
pointed out that the akinesis in the left ventricles of those pa-
tients was too large of an area to be attributed to the dysfunc-
tional microvessels’ supply (Vitale, et al. 2016). A corrected TIMI 
frame count was performed and found that the flow was slower 
in the left anterior descending artery and the researchers sug-
gested this being the source of akinesis in the apex while the 
base is relatively spared in TTC (Khalid, et al. 2015). However, 
the combined studies do not find microvascular dysfunction to 
be the primary source of TTC, but it is likely to play a role in 
the etiopathogenesis.
Catecholamine Theory
The catecholamine theory is perhaps the most well developed 
and significant theory of TTC. Many patients are noted to have 
grossly elevated plasma catecholamine levels, measuring at two 
to three times greater than in patients with myocardial infarc-
tions and twenty times higher than normal adults (Zeb, et al. 
2011). These elevations were noted of both adrenomedullary 
and sympathoneurally-derived catecholamines. The adrenal 
medulla releases epinephrine and norepinephrine after stress, 
which activates preganglionic sympathetic nerves. In addition, 
the peripheral sympathetic nerves release norepinephrine, both 
of which contribute to the β-adrenergic pathway. The common 
emotional or physical stressor in patients is tightly connected 
with this theory in its influx of catecholamines. Researchers 
concluded that the stressor induced hyperactivity of the sym-
pathetic nervous system and prompted the release of catechol-
amines into the patient’s blood stream (Tarkin, et al. 2008).
The apex of the left ventricle has higher adrenoceptor den-
sity than the base, presenting location specific evidence for the 
cardiomyopathy. The influx of catecholamines, both epinephrine 
and norepinephrine, are directed to the β-adrenergic path-
way. This pathway is specifically located at the apex of the left 
ventricle, likely to produce the heart’s fight or flight response 
of hypercontraction of the cardiomyocytes. The β-adrenergic 
receptors in the cell membranes bind to the catecholamines 
which ignites this response. The overstimulation of Gs (acti-
vator) through β2-coupling due to catecholamines can cause 
apoptosis of the myocytes. The process therefore switches to 
Gi (inhibitor) to protect the myocytes from further damage. 
This causes a decrease in contraction and results in the hypoki-
nesis of the apex of the left ventricle. There is serum evidence 
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of slight necrosis caused by the excess catecholamine in the 
minimally elevated troponin levels in patients with TTC. Studies 
showed that a signaling pathway known to exhibit anti-apop-
tosis functions, phosphatidyl inositol 3-kinase protien kinase 
B, presented increased activity. This may be the source of the 
quick recovery of the myocytes. In addition to this, the transient 
nature of this condition can be attributed to the inverse switch 
from Gi to Gs resulting in the expeditious recovery of systolic 
function in patients (Nef, et al. 2009). 
Another theory on the rapid recovery of the myocytes is relat-
ed to stem cells. A study using in vivo and in vitro cardiomyocytes 
and cardiac stem cells found that the cardiac stem cells were 
resistant to neurohumoral overstimulation. Researchers inject-
ed male Wistar rats with isoproterenol and noted left ventricle 
dysfunction in the subjects. The left ventricular function began 
to improve on day three post isoproterenol stimulation. β-ad-
renoreceptor hyperactivity from the catecholamine stimulation 
leads to PKA-mediated hyperphosphorylation of the ryadonine 
receptor 2, a calcium channel that mediates the release of Ca2+ 
from the sarcoplasmic reticulum to the cytoplasm. This hyper-
phosphorylation causes Ca2+ leakage which, in turn, produces 
myocyte damage. The cardiac stem cells have low levels of β-ad-
renergic receptors and do not express ryadonine receptor 2. This 
explains the resistance cardiac stem cells possess to the catechol-
amine overstimulation and the regeneration of cardiomyocytes 
that restore normal left ventricle function (Ellison, et al. 2007).
There is research that suggests specifically local release of 
catecholamines are at play in TTC. This is based on the find-
ings in a study performed on blood samples from both the 
aortic root and coronary sinus of patients with the condition. 
Catecholamine concentration was found to be higher in the 
coronary sinus signaling excessive local catecholamine release 
from the heart (Kume, et al. 2008).
Besides for emotional stressors, catecholamine excess result-
ing in TTC is precipitated by other factors like acute brain injury 
or treatment of respiratory distress. A study done on patients 
with subarachnoid hemorrhage reports of eight patients devel-
oping TTC as a result of a brain aneurysm rupture. Researchers 
theorize that at the time of the event, patients experience a 
catecholamine surge which can mediate cardiopulmonary dys-
function (Franco, et al. 2010). A case report presenting a patient 
with acute asthma exacerbation who was treated with β-2 ago-
nist nebulization and intravenous aminophylline. After fourteen 
hours of treatment she complained of shortness of breath and 
pain in her jaw. Testing showed classic TTC with ST segment 
elevation, T wave inversion, and left ventricular apical akinesia. 
The treatment was immediately stopped and replaced with ip-
ratropium nebulization and intravenous corticosteroids. After 
48 hours the echocardiogram revealed full recovery. Additional 
studies report that methylxanthines, the structural classifica-
tion of aminophylline, stimulate the release of catecholamines 
from the adrenal medulla and of norepinephrine from cardiac 
β-adrenergic nerve endings (Khwaja, Tai, 2016). Another study 
reports a similar case with a patient treated with nebulized 
adrenaline to manage an airway obstruction. Like the previous 
case study, this patient developed TTC post adrenaline treat-
ment (Keshtkar, et al. 2016). These reports present a medication 
administration that possibly caused a catecholamine surge sus-
pected to have induced the patients’ TTC.
While the catecholamine theory is the most developed and 
scientifically supported mechanism of TTC, not all patients are 
found to have elevated catecholamine levels, prompting contin-
ued investigation into a definitive pathogenesis of the condition 
(Tarkin, et al. 2008).
Low Estrogen Levels
The occurrence of TTC specifically in post-menopausal women 
prompted the investigation of estrogen deficiency as a pre-
disposing factor. One study demonstrated increased estrogen 
serum levels in rats weakened cardiac changes in response to 
immobilization stress. P44/p42 mitogen-activated protein kinase 
was activated by the immobilization stress along with the upreg-
ulation of immediate early genes in the myocardium. Immediate 
early genes are activated in response to cellular stimuli at the 
transcription level. The study theorizes that estrogen attenuat-
ed this process and inhibited the activation of the sympathetic 
nervous system by decreasing the formulation of immediate 
early genes in both the brain and heart (Ueyama, 2004). In a 
study published by this author more recently, it was determined 
that, in response to immobilization stress, ovariectomized rats 
that received estradiol did not experience a significant decrease 
in left ventricular contraction. The ovariectomized exposed to 
stress sans estradiol treatment did, however, experience per-
centage contraction reduction (Ueyama, et al. 2003). An evalu-
ation of women with TTC found that majority of the patients 
were post-menopausal and had not undergone estrogen re-
placement therapy. Researchers postulated that lack of estrogen 
replacement therapy may predispose women to TTC (Kuo, et al. 
2010). Combined, these studies propose that post-menopausal 
women, who experience a deficiency of estrogen, lack a protec-
tive barrier against the development of TTC.
Genetic Predisposition and the Catecholamine 
Theory
With analysis, the catecholamine theory appears problematic 
because not all patients experience this cardiac dysfunction 
with an emotional or physical stressor that may cause a cat-
echolamine surge. Genetic research introduced new theories 
that address this dilemma.  
The apparent exclusiveness of patients who develop TTC sug-
gests that the general population possesses a molecular mech-
anism that protects their cardiomyocytes from a catecholamine 
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surge and prevents necrosis. Bcl2-associated athanogene 3 
(BAG3) is a constituent of an autophagy pathway and one that 
allows for the degradation of intracellular components. A study 
found that it is expressed in response to various stressors and 
is therefore theorized to promote stress resistance. The abla-
tion of BAG3 in mice resulted in lethal cardiomyopathy shortly 
postnatal. The study found that BAG3 single-nucleotide poly-
morphisms resulted in TTC. It introduced a novel post-tran-
scriptional pathway that, in response to epinephrine treatment, 
leads to BAG3 expression. Micro-RNAs are fundamental in 
their role as repressors of messenger RNAs’ translation. The 
study describes miR-371a-5p, a pathway that binds miRNA to 
3’-untranslated region (3’-UTR) of the BAG3 gene. Epinephrine 
induces miR-371a-5p which leads to BAG3 upregulation in 
cardiomyocytes. However, this protective mechanism is lost in 
patients who possess a single nucleotide variant involving the 
3’-UTR in the BAG3 gene which alters the miR-371a-5p path-
way and eliminates its binding. This genetic variant of BAG3 is 
found in many patients with TTC and could explain the cardiac 
dysfunction post catecholamine (D’avenia, et al. 2015).
Further research into the catecholamine mechanism pro-
duced an underlying theory involving another genetic role in 
TTC. The study concluded that genetic susceptibility involving 
β-adrenergic signaling increased the risk of toxicity induced by 
catecholamines in TTC.
Researchers utilized technology involving the reprogramming 
of somatic cells into induced pluripotent stem cells (iPSC) to 
produce this conclusion. Reprogramming somatic cells of these 
patients allowed for differentiation into cardiomyocytes that 
could be experimented on.
The study involved healthy donors for controls and patients 
with TTC. The somatic cells of the Takotsubo patients were 
reprogrammed and expanded into high quality iPSC clones. 
Using Wnt modulation and metabolic selection, cells were then 
differentiated into cardiomyocytes (CMs). After three months, 
the iPSC-CMs were subjected to isoprenaline or epinephrine 
in order to replicate the catecholamine stimulation suspected 
to be experienced in patients with TTC. After analysis, studies 
showed that the catecholamine excess in the TTC iPSC-CMs 
was apparent in the increased expression of NR4A1, a cardiac 
stress-related gene. Compared to the control iPSC-CMs, the 
TTC iPSC-CMs recorded much greater expression of NR4A1 
post subjection to catecholamines. Three weeks after catechol-
amine administration, there was a reversal in changes to the 
NR4A1 expression. 
The researchers proceeded to investigate β-adrenergic sig-
naling using the TTC iPSC-CMs. They measured cAMP levels and 
PKA activation by phosphorylation and found increased levels 
in both compared to the control iPSC-CMs after catecholamine 
treatment. In addition, extracellular signal-regulated kinase 
was phosphorylated maximally in the TTC iPSC-CMs after 
epinephrine or isoprenaline treatment where the controls were 
significantly reduced in comparison. Increased lipid accumula-
tion was also noted in catecholamine treated TTC iPSC-CMs. 
Researchers examined the electrical activity of catecholamine 
treated iPSC-CMs from patients with TTC and found that more 
than half were silenced under certain isoprenaline concentra-
tions where only some of the controls were. For those that 
were not silenced, beating frequency was significantly increased 
in the TTC iPSC-CMs in comparison to the control subjects. 
The changes to the electrical activity was reversed following 
washout of the isoprenaline after 24 hours. 
Additionally, the study found that engineered heart muscles 
using the TTC iPSC-CMs presented an impaired force of con-
traction. Muscles also presented a higher sensitivity compared 
to control subjects to isoprenaline-stimulated inotropy, an al-
tering of the force of muscle contractions. Further investigation 
into the genetic makeup of the patients with TTC found variants 
in some patients’ genes that are key regulators of cardiac func-
tion. These findings may contribute to the hypothesis of a pre-
disposition to TTC, specifically involving catecholamine toxicity 
(Borchert, et al. 2017).
Conclusion
The pathogenesis of TTC is an evolving phenomenon with de-
veloping theories. While coronary artery spasm is found in some 
patients with TTC, the majority failed to experience induced 
coronary artery spasm with provocative testing. Microvascular 
dysfunction is a challenge to evaluate, but it has been found 
to be a contributing factor in many patients with TTC, though 
it is likely not the primary cause. Of the three theories pre-
sented, the catecholamine excess theory, supported by genetic 
research, and the estrogen deficiency theory is the most well 
developed pathogenic mechanism. In order to understand this 
cardiomyopathy in its entirety and to produce an appropriate 
treatment, more research is required involving integration of 
the cardiovascular, central neural, autonomic, and endocrine sys-
tems in their response to stress, and the genetic predisposition 
to TTC.
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